Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics Inc. (ADMA) is a commercial-stage biopharmaceutical company advancing plasma-derived therapies for immune deficiencies and infectious diseases. This dedicated news hub provides verified updates on corporate developments, regulatory milestones, and clinical progress.
Investors and healthcare professionals will discover timely coverage of earnings announcements, FDA decisions, manufacturing innovations, and strategic partnerships. Our curated selection emphasizes ADMA’s operational achievements in plasma collection, biomanufacturing excellence, and therapeutic pipeline advancements.
Key updates include product authorization progress, financial disclosures, patent developments, and peer-reviewed research findings. All content undergoes rigorous verification to ensure accuracy for investment and industry analysis.
Bookmark this page for direct access to ADMA’s official communications and expertly contextualized news. Maintain awareness of critical developments impacting this innovative biologics manufacturer through Stock Titan’s trusted reporting.
ADMA Biologics reported strong Q1 2025 financial results with total revenue of $114.8 million, up 40% year-over-year. The company achieved GAAP Net Income of $26.9 million (51% YoY increase) and Adjusted EBITDA of $47.9 million (81% YoY increase). ADMA received FDA approval for its yield enhancement process, expected to increase production output by 20% from the same plasma volume.
The company increased its guidance for FY 2025 and 2026, projecting total revenues of $500+ million and $625+ million respectively. ADMA authorized a $500 million share repurchase program, representing 8% of current market capitalization. The company's debt reorganization reduced cost of debt capital by 1.1%. ADMA now expects to achieve $1.1 billion in annual revenues before 2030, with anticipated margin expansion.
ADMA Biologics (Nasdaq: ADMA), a U.S.-based commercial biopharmaceutical company focused on specialty biologics, has scheduled its first quarter 2025 financial results announcement for May 7, 2025, after U.S. market close.
The company will host a live conference call and audio webcast at 4:30 p.m. ET on the same day. Participants must pre-register to receive dial-in numbers and a unique PIN, with recommended joining time being 10 minutes before the event start.
Two participation options are available:
- Interactive Q&A: Register to receive dial-in details and PIN
- Listen-only: Access the live webcast directly
An archived replay will be accessible in the investor section of ADMA's website under "Events & Webcasts."
ADMA Biologics (Nasdaq: ADMA) has received FDA approval for its innovative yield enhancement production process, marking a significant milestone for the biopharmaceutical company. The new process demonstrates an ability to increase production yields by approximately 20% from the same starting plasma volume, benefiting both ASCENIV and BIVIGAM products.
As the first U.S. producer of plasma-derived products to achieve this regulatory approval, ADMA expects meaningful acceleration in revenue and earnings trajectory beginning in late 2025 and accelerating into 2026. The company's internal R&D platform continues to advance, with ongoing development of novel pipeline programs including SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia.
ADMA Biologics (Nasdaq: ADMA) has issued a statement emphasizing its strategic advantage as a fully U.S.-based biopharmaceutical company amid recent tariff implementations. The company confirms that the new tariffs on foreign goods, services, and manufacturing will have no impact on its operations due to its entirely domestic supply chain and manufacturing infrastructure.
The company's President and CEO, Adam Grossman, highlighted that all manufacturing operations, end-market sales, and customer engagements are conducted exclusively within the United States. ADMA's vertically integrated supply chain, entirely based in the U.S., provides complete domestic control over sourcing, manufacturing, and distribution, aligning with increasing federal and private sector preferences for U.S.-made products.
ADMA Biologics reported exceptional financial results for FY 2024, with total revenue reaching $426.5 million, a 65% year-over-year increase. The company achieved a GAAP net income of $197.7 million, including an $84.3 million tax benefit. Adjusted EBITDA grew 309% to $164.6 million.
Key financial highlights include year-end cash position exceeding $103 million and $60 million of debt organically discharged in 2H 2024. The company provided increased guidance for FY 2025 and 2026, projecting revenues of over $490 million and $605 million respectively.
Strategic developments include securing long-term high-titer plasma supply contracts, expanding collection capacity 5-fold to approximately 250 centers. ADMA anticipates FDA approval of its yield enhancement production process by mid-2025, potentially increasing production yields by 20%. The company expects to achieve over $1 billion in annual revenue before 2030.
ADMA Biologics (Nasdaq: ADMA) has announced its participation in the upcoming Raymond James Institutional Investor Conference. The company's President and CEO, Adam Grossman, will engage in a fireside chat scheduled for March 5, 2025, at 11:35 a.m. ET.
Investors and interested parties can access the live audio webcast through the 'Events & Webcasts' section of ADMA's investor relations website at ir.admabiologics.com/events-webcasts. The archived version of the webcast will be made available approximately two hours after the event concludes.
ADMA Biologics (Nasdaq: ADMA) has scheduled its fourth quarter and full year 2024 financial results announcement for March 3, 2025, after U.S. financial markets close. The company's management team will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss financial results and provide company updates.
Interested participants can access the conference call by dialing (888) 596-4144 with conference ID 5201334. It's recommended to join approximately 10 minutes before the event starts. Those not planning to ask questions are encouraged to listen to the live webcast available on the company's website. An archived replay will be available in the investor section under "Events & Webcasts" at ir.admabiologics.com/events-webcasts.
ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics.
ADMA Biologics has announced its preliminary unaudited revenue for FY 2024, estimating a total revenue of approximately $417-425 million, exceeding its previous guidance of $415 million. The company's total cash holdings at year-end 2024 grew to more than $100 million, a $45 million increase quarter-over-quarter, despite organically discharging $30 million of debt during Q4 2024.
Newly executed high-titer plasma supply contracts are expected to support durable revenue growth for ASCENIV through the late 2030s. Additionally, ADMA has submitted a PAS to the FDA for approval of an innovative yield enhancement production process, with potential regulatory approval anticipated by mid-2025.
The company has provided revenue guidance for FY 2025 and 2026, expecting to exceed $485 million and $600 million, respectively. Net income for these years is projected to surpass $170 million and $230 million, while adjusted EBITDA is expected to exceed $220 million and $300 million, respectively. ADMA aims to generate over $1 billion in total annual revenue before 2030, more than doubling the current 2025 revenue forecast.
ADMA Biologics (Nasdaq: ADMA) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. The company's presentation is scheduled for Monday, January 13, 2025, at 10:30 a.m. PT.
As an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics, ADMA will make its presentation available through a live audio webcast accessible via the investor section of the company's website under 'Events & Webcasts'. An archived version of the webcast will be available approximately two hours after the event.
ADMA Biologics announced a $30 million partial paydown of its senior secured term loan facility with Ares Capital, using cash on hand. This represents the second paydown in four months, reducing the company's total gross debt by 29% to $75 million. The remaining debt consists of a $42.5 million revolving credit facility and $32.5 million outstanding under the term loan facility.
The company attributes this debt reduction to organically generated cash flow, and management expects the lowered interest expense to enhance earnings growth potential in upcoming periods. ADMA plans to continue optimizing its cost of both debt and equity capital moving forward.
FAQ
What is the current stock price of Adma Biologics (ADMA)?
What is the market cap of Adma Biologics (ADMA)?
